We’re pleased to welcome uro-oncology leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer. Relmada Therapeutics ($RLMD) is entering a critical phase in the development of NDV-01.
Read more: https://t.co/cJ1V9Vb5uL
Today at the @Jefferies Global Healthcare Conference in London, $RLMD CEO Sergio Traversa, CFO Maged Shenouda and Chief Business Officer Bipin Dalmia, PhD, will join a fireside chat at 7 a.m. ET / 12 p.m. GMT.
Register here: https://t.co/hkpC3msSf3
$RLMD is heading to London for the @Jefferies Global Healthcare Conference, November 16–19.
Relmada's management team will participate in a fireside chat on November 16 at 7 a.m. ET / 12 p.m. GMT.
Register here: https://t.co/hkpC3msSf3
#JefferiesHealthcare
Today at 4:30pm ET, Relmada will host a conference call and webcast to discuss Q3 2026 financial results and recent business progress.
Register to join the webcast: https://t.co/GoEsCaFotK $RLMD
Mark your calendars: This Thursday November 12 at 4:30 PM ET Relmada will host a conference call and webcast to discuss third quarter 2026 financial results and recent business progress.
Register for the webcast: https://t.co/dFHht8yPUa $RLMD
Relmada Therapeutics CEO Sergio Traversa and CFO Maged Shenouda will participate in a fireside chat at the @Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 12:00 PM GMT/7 AM ET.
Webcast details: https://t.co/LNMiSPPAsE $RLMD
Relmada Therapeutics announced plans to host a conference call and webcast on Thursday, November 12, 2026, at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress.
More details: https://t.co/tSc0UG3YuX $RLMD
Health information shouldn't just be available. It should be understandable.
As #HealthLiteracyMonth comes to a close, we're reflecting on the importance of communicating complex science and clinical development with clarity.
$RLMD
Prader-Willi syndrome is often discussed through the lens of hyperphagia, but its challenges can extend beyond a single symptom.
Relmada is developing sepranolone to target disorders linked to excess GABAergic activity, including PWS.
https://t.co/5KOOYSABSJ $RLMD
What makes intermediate-risk NMIBC a distinct treatment challenge?
The population can vary considerably in recurrence risk, and repeated recurrence may mean additional procedures over time. $RLMD
Did you know Relmada's story began as a spinout from Cornell University?
Originally founded with a focus on CNS, Relmada has evolved into a clinical-stage biotechnology company advancing programs across oncology and CNS disorders. $RLMD
IND. One important step in clinical development.
An Investigational New Drug application provides the regulatory pathway for an investigational therapy to advance into clinical study in the U.S.
Why does that matter for Relmada? ⬇️
https://t.co/19QKhy8YgT $RLMD
Clinical development comes with its own language. Understanding it matters.
This #HealthLiteracyMonth, we’re highlighting the importance of making complex health & scientific information clearer and more accessible.
Because progress is worth understanding, not just announcing.
Relmada ($RLMD) is in Boston this week for the Wells Fargo 21st Annual Healthcare Conference, September 8 - 10 and is available for one-on-one meetings. Investors attending can contact their representative to arrange a meeting. More details: https://t.co/P7FsH5TMWw
Relmada Therapeutics will participate in one-on-one meetings at the @WellsFargo 21st Annual Healthcare Conference in Boston, Sept. 8-10.
Investors interested in meeting with management should contact their Wells Fargo representative.
Learn more: https://t.co/P7FsH5TMWw $RLMD
Relmada Therapeutics is at the #IBCG26 Annual Retreat in Houston this weekend, joining the International Bladder Cancer Group and the wider urologic oncology community for meaningful discussions on the evolving management of bladder cancer. $RLMD
Innovation extends beyond the medicine itself. Drug delivery technology can play an important role in supporting treatment administration and patient care.
Learn more about NDV-01: https://t.co/HQfYZCe9Ah $RLMD
Clinical trials help researchers evaluate investigational therapies, expand scientific knowledge and advance potential new treatment options for patients.
Learn more about Relmada: https://t.co/V262MkuawP $RLMD
Some patients with #NMIBC stop responding to Bacillus Calmette-Guérin, the current standard treatment. Advancing new therapeutic approaches remains critical for these patients.
Learn more about Relmada's oncology pipeline: https://t.co/fPOZnUbRdu $RLMD